NORCEPT-E 1/35 21
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NORCEPT-E 1/35 21 (NORCEPT-E 1/35 21).
Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin secretion, preventing ovulation; progestin (norethindrone) alters cervical mucus, endometrial lining, and inhibits sperm penetration.
| Metabolism | Ethinyl estradiol: primarily metabolized by CYP3A4; norethindrone: primarily metabolized by CYP3A4 and reduction. |
| Excretion | Renal: 50-60% as metabolites (primarily ethinyl estradiol glucuronide and norethindrone metabolites); fecal: 20-30% via biliary elimination; unchanged drug: <5%. |
| Half-life | Ethinyl estradiol: terminal half-life approximately 17 hours (range 13-27 hours), consistent with once-daily dosing; norethindrone: terminal half-life approximately 7.6 hours (range 5-12 hours), permitting steady-state within 5 days. |
| Protein binding | Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 61-65% bound to albumin and SHBG. |
| Volume of Distribution | Ethinyl estradiol: 2.3-4.3 L/kg, indicating extensive tissue distribution; norethindrone: 3.4-4.2 L/kg, consistent with distribution beyond plasma volume. |
| Bioavailability | Oral: ethinyl estradiol 40-45% (first-pass metabolism); norethindrone 60-65% (first-pass metabolism). |
| Onset of Action | Oral: contraceptive effect begins after 7 days of continuous dosing; full suppression of ovulation by 10-14 days. |
| Duration of Action | Contraceptive effect persists for 24 hours with daily dosing; after last dose, ovulation may return within 2-4 weeks but can be delayed up to 3 months. |
One tablet (norethindrone 1 mg + ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no tablets. Repeat cycle continuously.
| Dosage form | TABLET |
| Renal impairment | No dosage adjustment required for mild to moderate renal impairment. Avoid use in severe renal impairment or end-stage renal disease due to potential fluid retention and hormonal metabolism alterations. |
| Liver impairment | Contraindicated in acute or chronic hepatic impairment (Child-Pugh class A, B, or C) due to impaired steroid hormone clearance and increased risk of adverse effects. |
| Pediatric use | Not indicated for use before menarche. For adolescent females, same dosing as adults: one tablet daily for 21 days, then 7 days off. Weight-based adjustments not required; use standard dosing if post-menarche. |
| Geriatric use | Not indicated for use after menopause. No specific dosing adjustments studied; avoid use in elderly due to increased risk of thromboembolic events and lack of benefit for postmenopausal contraception. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NORCEPT-E 1/35 21 (NORCEPT-E 1/35 21).
| Breastfeeding | Small amounts of oral contraceptive steroids have been identified in breast milk, with an estimated infant dose of 0.1% to 1% of the maternal daily dose. The milk-to-plasma ratio (M/P) for ethinyl estradiol is approximately 0.42 under steady-state conditions. Use of combined oral contraceptives during lactation may reduce milk production and breast milk quality, especially when initiated soon after delivery. Therefore, use of combined OCs is generally not recommended during breastfeeding, particularly in the first 6 months postpartum. Progestin-only preparations are preferred. |
| Teratogenic Risk | Epidemiological studies have not revealed an increased risk of birth defects in infants born to women who used oral contraceptives (OCs) before pregnancy or inadvertently during early pregnancy. However, OCs are contraindicated during pregnancy due to potential hormonal effects on the developing fetus. Use of OCs during the second and third trimesters is not associated with teratogenicity, but has been linked to an increased risk of fetal outcomes such as low birth weight and possibly congenital anomalies in some studies, though not consistently. The overall risk is considered low, but OCs should be discontinued if pregnancy is confirmed. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and smoking intensity (especially in women over 35). Women should not smoke while using this product.
| Serious Effects |
["Thrombophlebitis or thromboembolic disorders","History of deep vein thrombosis or pulmonary embolism","Cerebral vascular or coronary artery disease","Known or suspected breast cancer","Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior pill use","Hepatic adenoma or carcinoma","Known or suspected pregnancy","Current or past history of ischemic heart disease","Diabetes with vascular involvement","Headaches with focal neurological symptoms","Major surgery with prolonged immobilization","Known hypercoagulopathies","Uncontrolled hypertension","Smoking in women over 35 years","Severe renal disease"]
| Precautions | ["Increased risk of thromboembolic disorders","Cardiovascular disease risk","Carcinoma of breast and reproductive organs","Hepatic neoplasia","Elevated blood pressure","Gallbladder disease","Carbohydrate and lipid effects","Headache","Bleeding irregularities","Ectopic pregnancy","Depression"] |
Loading safety data…
| Fetal Monitoring | Monitoring during pregnancy: If inadvertent exposure occurs, no special fetal monitoring is typically required due to low teratogenic risk. However, if OC use continues inadvertently during pregnancy, baseline ultrasound and fetal growth monitoring may be considered. For lactation: No specific monitoring required, but observe infant for jaundice or fluid retention. In patients with risk factors (e.g., hypertension, diabetes), monitor blood pressure and blood glucose levels if OC is used postpartum. |
| Fertility Effects | Oral contraceptives are used for contraception and do not permanently impair fertility. After discontinuation, normal ovulation and fertility typically return within 1-3 cycles. There is no evidence of long-term adverse effects on fertility. In some cases, there may be a short delay in return of fertility due to return of spontaneous ovarian function, but this is usually transient. |